The start of a new year saw the launch of a consultation on NICE’s eagerly anticipated health inequalities modular update to the manual for health technology evaluation.1
Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis (ASM) by the NHS in England and Wales, including firs
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl